Intra Cellular Therapies Price Patterns

ITCIDelisted Stock  USD 131.87  0.03  0.02%   
As of 3rd of February 2026 The value of RSI of Intra-Cellular Therapies' share price is above 80 . This usually indicates that the stock is significantly overbought by investors. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards.

Momentum 88

 Buy Peaked

 
Oversold
 
Overbought
The successful prediction of Intra-Cellular Therapies' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Intra Cellular Therapies, which may create opportunities for some arbitrage if properly timed.
Using Intra-Cellular Therapies hype-based prediction, you can estimate the value of Intra Cellular Therapies from the perspective of Intra-Cellular Therapies response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Intra-Cellular Therapies to buy its stock at a price that has no basis in reality. In that case, they are not buying Intra-Cellular because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Intra-Cellular Therapies after-hype prediction price

    
  USD 131.87  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intra-Cellular Therapies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
101.46101.46145.06
Details
Naive
Forecast
LowNextHigh
134.87134.87134.87
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
131.73131.84131.96
Details

Intra-Cellular Therapies After-Hype Price Density Analysis

As far as predicting the price of Intra-Cellular Therapies at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Intra-Cellular Therapies or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Intra-Cellular Therapies, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Intra-Cellular Therapies Estimiated After-Hype Price Volatility

In the context of predicting Intra-Cellular Therapies' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Intra-Cellular Therapies' historical news coverage. Intra-Cellular Therapies' after-hype downside and upside margins for the prediction period are 131.87 and 131.87, respectively. We have considered Intra-Cellular Therapies' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
131.87
131.87
Downside
131.87
After-hype Price
131.87
Upside
Intra-Cellular Therapies is very steady at this time. Analysis and calculation of next after-hype price of Intra Cellular Therapies is based on 3 months time horizon.

Intra-Cellular Therapies Stock Price Outlook Analysis

Have you ever been surprised when a price of a Company such as Intra-Cellular Therapies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intra-Cellular Therapies backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Intra-Cellular Therapies, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
7 Events / Month
1 Events / Month
In about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
131.87
131.87
0.00 
0.00  
Notes

Intra-Cellular Therapies Hype Timeline

Intra Cellular Therapies is currently traded for 131.87. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Intra-Cellular is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Intra-Cellular Therapies is about 0.0%, with the expected price after the next announcement by competition of 131.87. About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.73. Intra Cellular Therapies had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 7 days.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

Intra-Cellular Therapies Related Hype Analysis

Having access to credible news sources related to Intra-Cellular Therapies' direct competition is more important than ever and may enhance your ability to predict Intra-Cellular Therapies' future price movements. Getting to know how Intra-Cellular Therapies' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Intra-Cellular Therapies may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
CTLTCatalent 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
BDXBecton Dickinson and 1.11 7 per month 0.84  0.07  2.93 (1.77) 7.14 
RVTYRevvity(2.56)9 per month 1.63  0.06  4.52 (3.04) 9.05 
KRTXKaruna Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
SWAVShockwave Medical 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
ABMDABIOMED 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
WBAWalgreens Boots Alliance 0.07 2 per month 0.07  0.11  0.71 (0.67) 2.25 
RXDXPrometheus Biosciences 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
IMGNImmunoGen 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
OSHOak Street Health 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 

Intra-Cellular Therapies Additional Predictive Modules

Most predictive techniques to examine Intra-Cellular price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Intra-Cellular using various technical indicators. When you analyze Intra-Cellular charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Intra-Cellular Therapies Predictive Indicators

The successful prediction of Intra-Cellular Therapies stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Intra Cellular Therapies, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Intra-Cellular Therapies based on analysis of Intra-Cellular Therapies hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Intra-Cellular Therapies's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Intra-Cellular Therapies's related companies.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Consideration for investing in Intra-Cellular Stock

If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra-Cellular Therapies' history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios